SEARCH

SEARCH BY CITATION

References

  • 1
    Yen HL, Webster RG. Pandemic influenza as a current threat. Curr Top Microbiol Immunol2009; 333:324.
  • 2
    Xu X, Subbarao K, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology1999; 261:1519.
  • 3
    World Organization for Animal Health. Update on highly pathogenic avian influenza in animals (type H5 and H7). Available at http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm (Accessed 6 February 2012).
  • 4
    World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 2011. Available at http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html (Accessed 6 February 2012).
  • 5
    Donis RO, Smith GJ, Perdue ML et al. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis2008; 14:e1.
  • 6
    World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness – February 2011. Wkly Epidemiol Rec2011; 86:93100.
  • 7
    Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis2006; 194:159167.
  • 8
    Ducatez MF, Bahl J, Griffin Y et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci USA2011; 108:349354.
  • 9
    Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis2006; 194:10401043.
  • 10
    Hoschler K, Gopal R, Andrews N et al. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza Other Respi Viruses2007; 1:199206.
  • 11
    Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis2008; 198:642649.
  • 12
    Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine2006; 24:65886593.
  • 13
    Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med2006; 3:e360.
  • 14
    Baras B, Stittelaar KJ, Kuiken T et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine2011; 29:20922099.
  • 15
    Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol2009; 83:77707778.
  • 16
    Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol2007; 81:35143524.
  • 17
    Schwartz JA, Buonocore L, Suguitan AL Jr et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol2010; 84:46114618.
  • 18
    Wood JS, Robertson JS. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respi Viruses2007; 1:59.
  • 19
    Abelin A, Colegate T, Gardner S, Hehme N, Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry’s perspective. Vaccine2011; 29:11351138.
  • 20
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72:248254.
  • 21
    World Health Organization. WHO manual on animal diagnosis and surveillance. 2011. Available at http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf (Accessed 21 October 2011).
  • 22
    Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg1938; 27:493497.
  • 23
    Goji NA, Nolan C, Hill H et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis2008; 198:635641.
  • 24
    Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis2005; 191:12101215.
  • 25
    Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine2010; 28:849857.
  • 26
    Lin JT, Li CG, Wang X et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis2009; 199:184187.
  • 27
    Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis2001; 183:368376.
  • 28
    Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine2010; 29:166173.
  • 29
    Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol2008; 180:17581768.
  • 30
    Lee LY, Ha do LA, Simmons C et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest2008; 118:34783490.
  • 31
    Goy K, Von Bibra S, Lewis J et al. Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. Influenza Other Respi Viruses2008; 2:115125.
  • 32
    Dormitzer PR, Galli G, Castellino F et al. Influenza vaccine immunology. Immunol Rev2011; 239:167177.
  • 33
    LaMere MW, Lam HT, Moquin A et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol2011; 186:43314339.